文献速递免疫规划

两种PCV2疫苗免疫后的细胞与体液免疫及强毒PCV2d攻毒研究

Cellular and humoral immunity following vaccination with two different PCV2 vaccines (containing PCV2a or PCV2a/PCV2b) and challenge with virulent PCV2d.
PubMed 文献 · Vaccine · 2021-08-19

本研究评估了含PCV2a或PCV2a/PCV2b的两种猪圆环病毒2型疫苗(三价嵌合疫苗与二价重组疫苗)免疫后的体液与细胞免疫应答,并以强毒PCV2d攻毒。结果显示三价嵌合疫苗在单剂或分两剂接种后均诱导强劲的细胞免疫和保护效力,所有免疫组攻毒后均产生抗体应答。

要点

  • 三价嵌合PCV2疫苗单剂或分两剂均诱导强劲细胞免疫和保护效力
  • 二价重组疫苗仅在第二剂后诱导低但可检测的PCV2特异性IFN-γ应答
  • 所有免疫组在攻毒后均产生稳健抗体应答

核心结论

  • 三价嵌合PCV2疫苗单剂或分两剂接种均诱导强劲细胞免疫和保护效力。

研究设计与样本

  • 实验性研究:猪只分为T01(安慰剂两剂)、T02(三价疫苗全剂量)、T03(三价疫苗分两剂)、T04(二价疫苗分两剂),两剂间隔三周,全部以强毒PCV2d攻毒。

主要发现

  • T02和T04在第二剂后产生稳健抗体应答,所有免疫组攻毒后均产生抗体应答。
  • T02和T03在第一剂后即诱导强劲PCV2特异性IFN-γ应答,T02在第二剂后仍强劲。
  • T04仅在第二剂后诱导低但可检测的PCV2特异性IFN-γ应答。
  • 研究第52天淋巴结细胞中,T01对replicase和PCV2d衣壳肽的IFN-γ应答显著更高,与未免疫猪的活跃病毒复制一致。

临床怎么用

  • 三价嵌合PCV2疫苗可采用单剂或分两剂接种方案以诱导细胞免疫和保护效力。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Porcine Circovirus type 2 (PCV2) associated disease is one of the most economically important swine diseases worldwide. Vaccines reduce PCV2 disease by inducing humoral immunity (neutralizing antibodies) and cell-mediated immunity (CMI) but may be improved by optimizing the immune response they induce. This study evaluated immune responses to a trivalent inactivated Porcine Circovirus (PCV) Type 1-Type 2a chimera (cPCV2a), cPCV2b and Mycoplasma hyopneumoniae (MH) (an experimental serial of Fostera® Gold PCV MH, also marketed as Circomax® Myco) vaccine or a bivalent recombinant PCV2a baculovirus expressed ORF2 capsid plus MH vaccine (Circumvent® PCV-M G2). Treatment Groups (T) received two doses of placebo (T01), one full or two split doses of the trivalent vaccine (T02, T03) or two split doses of the bivalent vaccine (T04) where two doses were given, there was a three-week period between administrations. All pigs were challenged with a virulent field isolate of PCV2d. CMI was measured as PCV2-specific IFN-γ secreting cells in blood and lymph node. Humoral immunity was measured as PCV2 antibodies. Vaccine efficacy was determined as viremia and fecal shedding of virus. There was a robust antibody response in T02 and T04 post the second vaccination and all vaccinated groups post challenge. There was a robust PCV2-specific IFN-γ response following the 1st dose in T02 and T03 and after the second dose in T02. T04 induced a low but detectable PCV2-specific IFN-γ response only after the 2nd dose. Among lymph node cells (study day 52), there was a significantly higher PCV2-specific, IFN-γ response to replicase and PCV2d capsid peptides in T01, consistent with active viral replication in non-vaccinated pigs. The trivalent chimeric vaccine induced robust CMI and protective efficacy, following a one dose regimen or splitting the dose into two vaccine administrations.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Venegas-Vargas C, Taylor LP, Foss DL, et al. Cellular and humoral immunity following vaccination with two different PCV2 vaccines (containing PCV2a or PCV2a/PCV2b) and challenge with virulent PCV2d. Vaccine. 2021. PMID: 34420789. doi:10.1016/j.vaccine.2021.08.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。